AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma

CAMBRIDGE, Mass. --  AVEO Oncology (NASDAQ:AVEO) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has recommended FOTIVDA™ (tivozanib) for approval as a treatment for patients with advanced renal cell carcinoma (RCC). The CHMP's recommendation is now referred to the European Commission (EC). The EC, which typically adheres to the recommendation of the CHMP, but is not obligated to do so, is expected to make its final decision in about 67 days. If approved by the EC, marketing authorization for tivozanib will be granted in all 28 countries of the European Union, Norway, Iceland and Liechtenstein. EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, is the European licensee for tivozanib.
Published: 23 June 2017
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: AVEO Oncology ( AVEO )

DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

VANCOUVER, British Columbia and MENLO PARK, Calif., June 22, 2017  -- DelMar Pharmaceuticals (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced it has received Institutional Review Board (IRB) approval to conduct its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (STAR-3). 
 
"IRB approval is an essential step in initiating patient enrollment in our Phase 3 trial," stated Jeffrey Bacha DelMar's chairman & CEO.  "We are pleased to remain on track to open enrollment in this trial at leading centers in the United States.  Based on our research, we believe that VAL-083 offers significant potential as a new therapy for GBM patients who currently have no viable treatment options." 
Published: 22 June 2017
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: DelMar Pharmaceuticals ( DMPI )

Trovagene Announces Agreement with Global Biopharmaceutical Company to Utilize Trovera ® ctDNA Tests and Services in Cancer Clinical Trials

SAN DIEGO, June 22, 2017  -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced it has entered into an agreement with a worldwide, premier biopharmaceutical company to provide Trovera® urine circulating tumor DNA (ctDNA) biomarker tests and services. 
 
The Trovera® urine and blood liquid biopsy tests will be used to assess and monitor mutation status in clinical trials of potential first-in-class or best-in-class oncology therapeutics in development.
 
"We're pleased to have our liquid biopsy tests included in the clinical trials with a leading biopharmaceutical company and to participate in their development of transformative therapies to improve the lives of cancer patients worldwide," said Bill Welch, Chief Executive Officer of Trovagene.  "This agreement follows a separate, recent announcement of our collaboration with AstraZeneca and demonstrates the value of our Trovera® biomarker technology."
Published: 22 June 2017
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Trovagene Inc ( TROV )

Moleculin Announces Significant Discovery with Potential to Treat Pancreatic Cancer

Metabolic Inhibitor Shows Greater Ability to Kill Pancreatic Cancer Cell Lines
 
HOUSTON, TX--(Marketwired - June 21, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced the discovery of a metabolic inhibitor with the potential to treat pancreatic cancer.
 
"We've received a lot of attention from the scientific community for our glucose decoy technology (WP1122 Portfolio, Moleculin Presents Preclinical Data of Novel Inhibitor of Glycolysis at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, December 13, 2016) as a potential means to starve tumors to death by exploiting their hyper-dependence on glycolysis for energy production," commented Walter Klemp, Chairman and CEO of Moleculin, "and now we have identified possible new properties of our compound WP1234, a modification to WP1122.
Published: 21 June 2017
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Moleculin Biotech Inc ( MBRX )

BIOREM Announces Strategic Partnership to Market Ultrafiltration Membranes

GUELPH, ON, June 20, 2017 – BIOREM Inc. (TSX-V: BRM) ("BIOREM" or "the Company") announces that it has entered into a strategic partnership with Tus-Material Group to market globally their ultrafiltration membranes.  
 
Ultrafiltration membranes provide a barrier to contaminants in water including suspended solids and pathogens such as cryptosporidium, E. coli, and viruses.  Tus-Material Group membranes offer specific advantages over competitive filtration membranes in the market, including higher productivity, greater strength and ability to treat a wide water quality range.  Their ultrafiltration membranes are used in all aspects of water treatment, including filtration of surface water, pre-treatment of seawater for purification using reverse osmosis, and filtration of secondary effluents and industrial water streams for recycle. 
Published: 20 June 2017
Written by Editor
Up on News   TSXV   biotech  
Read more: BIOREM Inc ( BRM )
  1. IsoRay Inc ( ISR )
  2. Spherix Incorporated ( SPEX )
  3. Clovis Oncology ( CLVS )
  4. Selecta Biosciences ( SELB )
  5. MabVax Therapeutics Holdings ( MBVX )